Marker Therapeutics (MRKR) Operating Expenses (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Operating Expenses of $4.1 million for Q1 2026, down 17.86% year-over-year from $5.0 million in Q1 2025, and up 36.32% quarter-over-quarter from $3.0 million in Q4 2025.
Marker Therapeutics (MRKR) Operating Expenses (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Operating Expenses for 17 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 17.86% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $15.6 million (down 17.6% YoY), while the FY2025 annual figure was $16.4 million, down 7.18% from the prior year.
- Operating Expenses improved to $4.1 million in Q1 2026 per MRKR's latest filing, from $3.0 million in the prior quarter.
- Across five years, Operating Expenses topped out at $10.8 million in Q1 2022 and bottomed at $3.0 million in Q4 2025.
- Historically, Operating Expenses has averaged $4.9 million across 5 years, with a median of $4.3 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Expenses sank 65.49% — and 2024, when it soared 53.05%.
- Marker Therapeutics' Operating Expenses stood at $3.8 million in 2022, then advanced by 5.17% to $4.0 million in 2023, then jumped by 53.05% to $6.1 million in 2024, then sank by 51.13% to $3.0 million in 2025, then soared by 36.32% to $4.1 million in 2026.
- Business Quant data shows MRKR's Operating Expenses at $4.1 million in Q1 2026, $3.0 million in Q4 2025, and $3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | 2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.07 Mn |
| Dec 31, 2025 | 2.99 Mn |
| Sep 30, 2025 | 3.37 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Mar 31, 2025 | 4.96 Mn |
| Dec 31, 2024 | 6.11 Mn |
| Sep 30, 2024 | 4.33 Mn |
| Jun 30, 2024 | 3.48 Mn |
| Mar 31, 2024 | 3.79 Mn |
| Dec 31, 2023 | 3.99 Mn |
| Sep 30, 2023 | 3.46 Mn |
| Jun 30, 2023 | 4.90 Mn |
| Mar 31, 2023 | 5.54 Mn |
| Dec 31, 2022 | 3.80 Mn |
| Sep 30, 2022 | 6.83 Mn |
| Jun 30, 2022 | 6.06 Mn |
| Mar 31, 2022 | 10.76 Mn |
| Dec 31, 2021 | 11.01 Mn |
| Sep 30, 2021 | 10.02 Mn |
| Jun 30, 2021 | 10.91 Mn |